Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Employees

291

Sector

Biotechnology & Medical Research

Calendar

04/03 - Q4 2025 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 02:30:00 30/12/2025 am IST			5-day change	1st Jan Change
90.00 ^USD	-7.14%		-.--%	-

30/12	Merus N.V.(NasdaqGM:MRUS) dropped from NASDAQ Composite Index	CI
29/12	Genmab scraps development of experimental cancer therapy	RE

Capitalization	682.62Cr 575.32Cr 526.56Cr 500.31Cr 927.66Cr 62TCr 959.02Cr 6.07TCr 2.42TCr 30TCr 2.56TCr 2.51TCr 1,04700Cr	P/E ratio 2026 *	-15.2x	P/E ratio 2027 *	-19.8x
Enterprise value	682.62Cr 575.32Cr 526.56Cr 500.31Cr 927.66Cr 62TCr 959.02Cr 6.07TCr 2.42TCr 30TCr 2.56TCr 2.51TCr 1,04700Cr	EV / Sales 2026 *	2,275x	EV / Sales 2027 *	152x
Free-Float	97.53%	Yield 2026 *	-	Yield 2027 *	-

30/12	Merus N.V.(NasdaqGM:MRUS) dropped from NASDAQ Composite Index	CI
29/12	Genmab scraps development of experimental cancer therapy	RE
17/12	Merus N.V.(NasdaqGM:MRUS) dropped from S&P Global BMI Index	CI
12/12	Merus N.V. Appoints Van De Winkel as Chief Executive Officer, Effective December 12, 2025	CI
12/12	Merus N.V. Announces Board Changes	CI
12/12	Genmab Finalizes Tender Offer for Dutch Biotech Merus	MT
12/12	Genmab Completes Acquisition of Merus – Bolsters Portfolio with New Cancer Treatment	FW
12/12	Genmab: Completion of Tender Offer for Outstanding Common Shares of Merus N.V.	RE
11/12	Merus N.V.(NasdaqGM:MRUS) dropped from NASDAQ Biotechnology Index	CI
11/12	Genmab A/S completed the acquisition of Merus N.V. in a tender offer transaction.	CI
04/12	Genmab Closes $2.5 Billion Senior Notes Offering	MT
04/12	Genmab A/S and Genmab Finance LLC Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes	CI
19/11	Genmab Unit Prices $2.5 Billion Senior Notes Offering	MT

06/25/06	Leerink Partners Downgrades Merus to Market Perform From Outperform, Adjusts PT to $97 From $95	MT
30/25/30	Barclays Downgrades Merus to Equalweight From Overweight, Adjusts Price Target to $97 From $112	MT
30/25/30	Guggenheim Downgrades Merus to Neutral From Buy, Adjusts Price Target to $97 From $109	MT
30/25/30	BMO Capital Downgrades Merus to Market Perform From Outperform, Adjusts Price Target to $97 From $110	MT
29/25/29	HC Wainwright Downgrades Merus to Neutral From Buy, Price Target at $97	MT

Merus N.V. Share Price

Equities

MRUS

NL0011606264

Biotechnology & Medical Research

Valuation: Merus N.V.

Chart: Merus N.V.

Latest news: Merus N.V.

Last Transcript: Merus N.V.

Analysts' recommendations: Merus N.V.

Press Releases: Merus N.V.

News in other languages: Merus N.V.

Quotes and Performance

Course Extremes

Managers and Directors: Merus N.V.

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

16/12	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B	AQ
17/11	Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab	PR
13/11	Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights	PR
24/25/24	Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety	GL
23/25/23	Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS	BU

25/25/25	Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid
24/25/24	HBM Healthcare confirme avoir redressé la barre à mi-parcours
15/25/15	Op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics kondigt Merus de publicatie aan van het abstract over petosemtamab in gemetastaseerde colorectale kanker
13/25/13	Merus kondigt de selectie aan van het abstract: Petosemtamab in Metastatic Colorectal Cancer (petosemtamab in gemetastaseerde colorectale kanker) voor mondelinge presentatie in de plenaire sessie op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
30/25/30	Nanobiotix, Genmab et Valneva grimpent, Asos déçoit

1 year	33.19	97.14
3 years	17.09	97.14
5 years	12.03	97.14
10 years	7.26	97.14

Manager	Title	Age	Since
Jan van de Winkel CEO	Chief Executive Officer	65	12/12/2025
Gregory Perry DFI	Director of Finance/CFO	65	14/06/2023
Fabian Zohren CTO	Chief Tech/Sci/R&D Officer	50	01/07/2024

Director	Title	Age	Since
Jan van de Winkel BRD	Director/Board Member	65	12/12/2025
Gregory David Emil Mueller BRD	Director/Board Member	54	12/12/2025
Anthony Pagano BRD	Director/Board Member	48	12/12/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MERUS N.V.	-7.14%	-.--%	+124.38%	+411.65%	682.6Cr
ARGENX SE	-1.16%	-2.34%	+13.14%	+101.15%	5.16TCr
WUXI APPTEC CO., LTD.	+0.78%	+6.83%	+77.60%	+13.78%	4.39TCr
INSMED INCORPORATED	-0.08%	-2.63%	+85.79%	+656.52%	3.17TCr
BIONTECH SE	+0.41%	+0.56%	-4.47%	-22.71%	2.73TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	+14.45%	+100.19%	-33.48%	2.12TCr
GENMAB A/S	-2.92%	-6.25%	+37.09%	-30.26%	1.9TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.33%	+1.81%	+139.66%	-	1.3TCr
AKESO, INC.	-1.33%	+2.47%	+77.44%	+132.47%	1.25TCr
SUMMIT THERAPEUTICS INC.	0.00%	+5.76%	-20.07%	+555.91%	1.18TCr
Average	-1.00%	+2.08%	+63.07%	+198.34%	2.39TCr
Weighted average by Cap.	-0.37%	+1.30%	+54.04%	+158.22%

	2026 *	2027 *
Net sales	30L 25.28L 23.14L 21.99L 40.77L 27Cr 42.15L 2.67Cr 1.07Cr 13Cr 1.13Cr 1.1Cr 46Cr	4.5Cr 3.79Cr 3.47Cr 3.3Cr 6.12Cr 408.39Cr 6.32Cr 40Cr 16Cr 196.35Cr 17Cr 17Cr 689.89Cr
Net income	-46Cr -39Cr -36Cr -34Cr -63Cr -4.19TCr -65Cr -410.96Cr -164.08Cr -2.02TCr -173.27Cr -169.71Cr -7.08TCr	-44Cr -37Cr -34Cr -32Cr -59Cr -3.95TCr -61Cr -386.94Cr -154.49Cr -1.9TCr -163.14Cr -159.79Cr -6.67TCr
Net Debt	-	-

1 day	-7.14%
3 months	-5.74%
6 months	+39.32%